Fabrazyme Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The fabrazyme market size has grown rapidly in recent years. It will grow from $1.26 million in 2025 to $1.43 million in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to lack of curative options for fabry disease, early success of enzyme replacement therapy, improved survival outcomes, regulatory orphan drug incentives, adoption by metabolic disease specialists.

The fabrazyme market size is expected to see rapid growth in the next few years. It will grow to $2.35 million in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to rising awareness of fabry disease, improved genetic screening programs, expansion of specialty rare disease clinics, long term treatment adherence focus, continued investment in orphan drug development. Major trends in the forecast period include growing use of enzyme replacement therapies, increased focus on rare genetic disease management, expansion of long term fabry disease treatment, rising emphasis on early diagnosis and intervention, improved multisystem disease monitoring approaches.

The increasing prevalence of genetic disorders is expected to drive the growth of the Fabrazyme market in the coming years. Genetic disorders are health conditions caused by abnormalities in an individual’s DNA. The rise in genetic disorders is primarily attributed to advances in diagnostic technologies that identify more cases, as well as factors such as delayed parenthood, environmental influences, and lifestyle changes that contribute to genetic mutations. Fabrazyme, an enzyme replacement therapy, supports patients with Fabry disease - a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A - by supplying the missing enzyme to break down accumulated lipids in the body. This reduces the risk of organ damage, alleviates symptoms, and improves overall quality of life. For instance, in March 2024, according to Gene People, a UK-based registered charity, over 6,000 genetic conditions are diagnosed in the UK, affecting approximately 1 in 25 children, resulting in around 30,000 new diagnoses annually, and more than 2.4 million people currently live with a genetic condition. Therefore, the rising cases of genetic disorders are driving the Fabrazyme market.

The growing adoption of personalized medicine is expected to further propel the growth of the Fabrazyme market. Personalized medicine is a healthcare approach that tailors treatment and medical strategies to the individual characteristics of each patient, including their genetic profile, environment, and lifestyle, to achieve precise and effective outcomes. The rise of personalized medicine is driven by advancements in genomic technologies, increased understanding of molecular biology, wider availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Fabrazyme supports personalized medicine by providing enzyme replacement therapy that is tailored to the specific genetic and metabolic needs of patients with Fabry disease, enhancing treatment efficacy, improving clinical outcomes, and promoting individualized care strategies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant increase from six approvals in 2022. Therefore, the growth of personalized medicine is driving the Fabrazyme market.

Rising healthcare expenditure is also expected to support the growth of the Fabrazyme market going forward. Healthcare expenditure refers to the total financial resources spent on healthcare services and related activities within a given period, typically measured annually. The increase in healthcare spending is driven by factors such as an aging population, the growing prevalence of chronic diseases, higher service costs, increased demand, technological advancements, rising drug prices, medical inflation, and the impact of events such as COVID-19. Fabrazyme benefits from this expenditure by enabling effective management of Fabry disease through enzyme replacement therapy, reducing the need for costly emergency interventions and long-term complications, and ultimately improving patient outcomes, thereby justifying investment in the therapy. For instance, in April 2025, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending rose by 6.5% in nominal terms from 2023 to 2024, and by 2.4% in real terms after adjusting for inflation. Therefore, rising healthcare expenditure is driving the growth of the Fabrazyme market.

Major companies operating in the fabrazyme market are Sanofi S.A., JCR Pharmaceuticals, mAbxience.

North America was the largest region in the Fabrazyme market in 2025. The regions covered in the fabrazyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fabrazyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the fabrazyme market by increasing costs for imported enzyme production materials and biologic processing equipment. These impacts are most visible in hospital based infusion programs across europe and north america. Higher tariffs have contributed to pricing pressures for rare disease biologics. However, they are also encouraging domestic enzyme manufacturing investments. This supports long term supply reliability for fabry disease treatment.

The fabrazyme market research report is one of a series of new reports that provides fabrazyme market statistics, including fabrazyme industry global market size, regional shares, competitors with a fabrazyme market share, detailed fabrazyme market segments, market trends and opportunities, and any further data you may need to thrive in the fabrazyme industry. This fabrazyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fabrazyme is a prescription therapy used mainly to treat Fabry disease, a genetic disorder resulting from a deficiency of the enzyme alpha-galactosidase A. This deficiency causes the buildup of a fatty substance called globotriaosylceramide (GL-3) in various tissues, leading to serious health complications such as kidney damage, heart issues, and neurological problems.

The primary strengths of Fabrazyme are 5 mg/vial and 35 mg/vial. The 5 mg/vial formulation contains a single-dose vial with 5 milligrams of the active ingredient, agalsidase beta. Its applications include use in hospitals and drug stores, and the medication is intended for both pediatric and adult patients.

The fabrazyme market consists of sales of the enzyme replacement therapy (ERT) known as Fabrazyme (agalsidase beta), Replagal (agalsidase alpha), Oral Chaperone Therapies, Substrate Reduction Therapies (SRT). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.